4-(Butylamino)-1-ethyl-1,7-dihydro-7-hydroxy-5H-furo[3,4-e]pyrazolo[3,4-b]pyridin-5-one | 64845-46-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: 4-(Butylamino)-1-ethyl-1,7-dihydro-7-hydroxy-5H-furo[3,4-e]pyrazolo[3,4-b]pyridin-5-one
• 英文别名: 8-(butylamino)-4-ethyl-12-hydroxy-11-oxa-2,4,5-triazatricyclo[7.3.0.03,7]dodeca-1(9),2,5,7-tetraen-10-one
• CAS: 64845-46-1
• 化学式: C₁₄H₁₈N₄O₃
• 分子量: 290.322
• InChiKey: CGJSSCMIRBKUPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  89.3
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  10-Chloro-3-ethyl-7,12-dimethyl-7,12-dihydropyrazolo-[4',3':5,6]pyrido[4,3-b][1,5]benzodiazepin-6(3H)-one 、 前列地尔 生成 4-(Butylamino)-1-ethyl-1,7-dihydro-7-hydroxy-5H-furo[3,4-e]pyrazolo[3,4-b]pyridin-5-one
  参考文献：
  名称：

  Inhibition of blood platelet aggregation

  摘要：

  使用某些环磷酸腺苷单磷酸酯酶（PDE）的抑制剂与PGE.sub.1联合使用可以增强PGE.sub.1抑制血小板聚集的活性。

  公开号：

  US04051236A1

文献信息

• Pharmaceutical Formulations comprising 1-substituted imidazoles, 1-substituted imidazoles and 1-substituted imidazoles for use in the treatment or prophylaxis of thrombo-embolic disorders
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0000951A1

  公开（公告）日：1979-03-07

  The invention relates to the use in medicine of 1-alkylimidazoles of formula in which A is a straight or branched, saturated or unsaturated acyclic hydrocarbon radical of from 1 to 3 carbon atoms; n is 0 or 1; and R is a cycloalkyl or cycloalkenyl radical of from 4 to 9 carbon atoms and optionally substituted by one, two, three or more alkyl radicals each containing from 1 to 4 carbon atoms, or, when n is 1, A and R together form an alkyl radical of from 4 to 7 carbon atoms or an alkenyl or alkynyl radical of from 4 to 9 carbon atoms, the imidazole being the free base or a pharmaceutically acceptable salt thereof. The 1-alkylimidazoles in which n is 0 and R ist cycloalkyl or cycloalkenyl are novel, as are those when A and R together form an alkenyl radical. Methods of preparing the 1-alkylimidazoles are disclosed. The 1-alkylimidazoles have pharmacological properties of use in medicine, in particular for the treatment or prophylaxis of thrombo-embolic disorders.

  本发明涉及式 1-烷基咪唑的医药用途。 其中 A 是 1 至 3 个碳原子的直链或支链、饱和或不饱和的无环烃基；n 是 0 或 1；和 R 是 4 至 9 个碳原子的环烷基或环烯烃基，并可选择被一个、两个、三个或多个烷基取代，每个烷基含有 1 至 4 个碳原子，或者，当 n 为 1 时，A 和 R 共同形成 4 至 7 个碳原子的烷基或 4 至 9 个碳原子的烯基或炔基，咪唑为游离基或其药学上可接受的盐。 n为0、R为环烷基或环烷烯基时的1-烷基咪唑是新颖的，A和R共同形成烯基时的1-烷基咪唑也是新颖的。 本发明公开了制备 1-烷基咪唑的方法。 1-烷基咪唑具有药理特性，可用于医药，特别是用于治疗或预防血栓栓塞性疾病。
• Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations thereof
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0003732A2

  公开（公告）日：1979-09-05

  The invention relates to I-arylalkylimidazoles of formula in which A is a straight or branched alkylene group of from 1 to 3 carbon atoms, or a straight or branched alkenylene or alkynylene group of 2 or 3 carbon atoms, n is an integer which is at least 1, and the or each R substituent, which when n is greater than 1 may be the same or different, is a saturated alkyl group of from 1 to 4 carbon atoms or an unsaturated alkyl group of from 2 to 4 carbon atoms, with the proviso that when A is unsaturated, R may also be alkoxy of from 1 to4 carbon atoms; (when n is at least 2) alkylenedioxy of from 1 to 4 carbon atoms; halo; trihalomethyl; hydroxy; carboxyl; a salt of such a carboxyl group; carboalkoxy; carboaryloxy; carboarylalkyloxy; -NR6R7 or -CONR6R7, in which R6 and R7 may be the same or different and are hydrogen or alkyl of from 1 to 4 carbon atoms; or an acid addition salt of such a I-arylalkylimidazole. Methods of preparing these 1-arylalkylimidazoles are disclosed. The I-arylalkylimidazoles have pharmacological properties of use in medicine, in particular for the treatment of prophylaxis ofthrombo-embolic disorders.

  本发明涉及 I-芳基烷基咪唑，其式如下 其中 A 是 1 至 3 个碳原子的直链或支链亚烷基，或 2 或 3 个碳原子的直链或支链烯基或亚炔基；n 是至少 1 的整数；或每个 R 取代基（当 n 大于 1 时可以相同或不同）是 1 至 4 个碳原子的饱和烷基或 2 至 4 个碳原子的不饱和烷基，但当 A 为不饱和基时，R 也可以是 1 至 4 个碳原子的烷氧基；(当 n 至少为 2 时）1 至 4 个碳原子的亚烷基二氧基；卤素；三卤甲基；羟基；羧基；此类羧基的盐；羧基烷氧基；羧基芳氧基；羧基芳烷氧基；-NR6R7 或-CONR6R7，其中 R6 和 R7 可以相同或不同，并且是氢或 1 至 4 个碳原子的烷基；或此类 I-芳基烷基咪唑的酸加成盐。 本发明公开了制备这些 1-芳烷基咪唑的方法。 I-芳基烷基咪唑具有药理特性，可用于医药，特别是用于治疗血栓栓塞性疾病的预防。
• Pharmacologically active N-amino hydantoin derivatives, their synthesis and intermediates
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0126849A1

  公开（公告）日：1984-12-05

  The hydantoins of formula (I) and their esters, amides, salts and solvates have prostaglandin mimetic and antagonistic properties rendering them useful in medicine. In formula (I) Z is hydrogen or alkyl; Z1 represents a group of formula -CH2-X-X1-X2 wherein, X is selected from -(CH2)2-, and cis and trans -CH=CH-, X' is a covalent bond or a straight or branched alkylene chain having 1 to 6 carbon atoms optionally having one of its methylene groups replaced by oxa (-0-) or thia (-S-) provided that at least one carbon atom separates the oxa or thia group from a carboxyl or -CH=CH- group, and X2 is a carboxyl group; and Z2 represents a group selected from -NH-CH2-R and -N=CH-R wherein, R is a group selected from -CO-Y and Y being a group selected from G3_8 alkyl, C3_8 alkenyl, phenyl-C1-4 alkyl and phenyl (wherein the phenyl group in both cases is optionally substituted by one or more groups independently selected from alkyl, alkoxy, nitro, halo and trihalomethyl), cycloalkyl of 4 to 8 carbon atoms, and 5- or 6- membered heterocyclic radicals containing at least one heteroatom selected from oxygen, sulphur and nitrogen; and Y' being a group selected from hydrogen, hydroxy, alkoxy and acyloxy.

  式 (I) 的 hydantoins 及其酯、酰胺、盐和溶液具有前列腺素模拟和拮抗特性，因此可用于医药。在式 (I) 中 Z 是氢或烷基； Z1 代表式-CH2-X-X1-X2 的基团，其中，X 选自-( )2-、顺式和反式-CH=CH-，X'是共价键或具有 1 至 6 个碳原子的直链或支链亚烷基链，其一个亚甲基可选择被氧杂（-0-）或硫杂（-S-）取代，条件是至少有一个碳原子将氧杂或硫杂基团与羧基或-CH=CH-基团隔开，且 X2 是羧基；以及 Z2 代表选自-NH- -R 和-N=CH-R 的基团，其中，R 是选自-CO-Y 和-CH=CH-R 的基团。 Y 是选自 G3_8 烷基、C3_8 烯基、苯基-C1-4 烷基和苯基（其中苯基在这两种情况下任选被一个或多个独立选自烷基、烷氧基、硝基、卤代和三卤甲基的基团取代）、4 至 8 个碳原子的环烷基和含有至少一个选自氧、硫和氮的杂原子的 5 或 6 成员杂环基的基团；以及 Y' 是选自氢、羟基、烷氧基和酰氧基的基团。
• Imidazole derivatives and salts thereof and their synthesis
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0000950B1

  公开（公告）日：1984-02-01
• Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0003560B1

  公开（公告）日：1984-05-02